These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11035135)

  • 21. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity.
    Caramaschi P; Biasi D; Carletto A; Manzo T; Randon M; Zeminian S; Bambara LM
    Rheumatol Int; 1996; 15(5):217-20. PubMed ID: 8717106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha and beta-blockade and beta-stimulation in Raynaud's syndrome: a double-blind, placebo controlled, single dose study.
    Cleophas TJ; Fennis JF; van 't Laar A
    Angiology; 1985 Apr; 36(4):219-25. PubMed ID: 2862814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enalapril in Raynaud's phenomenon.
    Janini SD; Scott DG; Coppock JS; Bacon PA; Kendall MJ
    J Clin Pharm Ther; 1988 Apr; 13(2):145-50. PubMed ID: 2839529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of brief cold exposure on finger dexterity and sensibility in subjects with Raynaud's phenomenon.
    Delp HL; Newton RA
    Phys Ther; 1986 Apr; 66(4):503-7. PubMed ID: 3960975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A 4 degrees C-1 min method of cold water immersion test for peripheral circulatory function in fingers].
    Ishitake T; Nakagawa K; Iwamoto J; Mori C; Matoba T
    Sangyo Igaku; 1992 Nov; 34(6):560-4. PubMed ID: 1460787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
    Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Raynaud's syndrome with adrenergic alpha-blockade with or without beta-blockade.
    Cleophas TJ; van Lier HJ; Fennis JF; van 't Laar A
    Angiology; 1984 Jan; 35(1):29-37. PubMed ID: 6141750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.
    Baart de la Faille H; van Weelden H; Banga JD; van Kesteren RG
    Arch Dermatol Res; 1986; 279(1):3-7. PubMed ID: 3545103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
    Fava A; Wung PK; Wigley FM; Hummers LK; Daya NR; Ghazarian SR; Boin F
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):925-9. PubMed ID: 22275160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea.
    Brouard R; Bossmar T; Fournié-Lloret D; Chassard D; Akerlund M
    BJOG; 2000 May; 107(5):614-9. PubMed ID: 10826575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic tests in Raynaud's phenomena in workers exposed to vibration: a comparative study.
    Olsen N
    Br J Ind Med; 1988 Jun; 45(6):426-30. PubMed ID: 3395577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects.
    Wollersheim H; Thien T
    J Clin Pharmacol; 1988 Dec; 28(12):1089-93. PubMed ID: 3243924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud's phenomenon.
    Holti G
    Curr Med Res Opin; 1979; 6(4):267-70. PubMed ID: 527352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non-peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non-pregnant women.
    Akerlund M; Bossmar T; Brouard R; Steinwall M
    Adv Exp Med Biol; 1998; 449():467-72. PubMed ID: 10026840
    [No Abstract]   [Full Text] [Related]  

  • 37. A non-invasive technique for the evaluation of peripheral circulatory functions in female subjects with Raynaud's phenomenon.
    Mirbod SM; Sugiura H
    Ind Health; 2017 Jun; 55(3):275-284. PubMed ID: 28321017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Hayward RA; Griffin MJ; Roath OS
    Br J Clin Pharmacol; 1991 Apr; 31(4):477-80. PubMed ID: 2049258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT).
    Huntgeburth M; Kießling J; Weimann G; Wilberg V; Saleh S; Hunzelmann N; Rosenkranz S
    Clin Drug Investig; 2018 Nov; 38(11):1061-1069. PubMed ID: 30238433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.